GLOBAL ACCESS TO HIGH-QUALITY PBMCs Download our PBMC Capabilities sheet A global network of highly-trained staff to isolate PBMCs per client-specific protocols and SOPs In the rapidly evolving landscape of biopharma drug development, the need for precise, reliable, and scalable cellular resources has never been more critical. At MLM Medical Labs, we specialize in providing

MLM Specialty Testing and Translational Services ACCELERATING INNOVATION THROUGH CUSTOMIZED SOLUTIONS At MLM, our scientists excel in collaboratively designing customized solutions to translate your specific research goals into practical therapeutic applications. We provide expert biomarker identification and validation, comprehensive assay development, tech transfer and validation, regulatory guidance, and project management to advance your novel therapeutics

Preclincal Model Development Fibrosis Models Overview Idiopathic pulmonary fibrosis MASH/NASH Systemic Sclerosis New Model Development Further in vivo models Interested in a new model or variation of an existing model? Creating a new preclinical model is a meticulous process that involves innovative scientific approaches. As an established preclinical CRO, we specialize in developing cutting-edge models

Fibrosis Models – IPF Fibrosis Models Overview Idiopathic pulmonary fibrosis MASH/NASH Systemic Sclerosis New Model Development Further in vivo models Bleomycin-induced Idiopathic Pulmonary Fibrosis (IPF) MLM Medical Labs offers an advanced Bleomycin-induced Lung Fibrosis model, established for over a decade in basic research on pulmonary fibrosis. Our methodology employs refined oral aspiration administration, facilitating uniform

Fibrosis Models Fibrosis Models Overview Idiopathic pulmonary fibrosis MASH / NASH Systemic Sclerosis New Model Development Further in vivo models Welcome to MLM Medical Labs, your premier partner for unraveling the complexities of fibrosis and its critical implications for various medical conditions. Fibrosis, characterized by excessive tissue scarring and stiffening, is a hallmark feature in

Fibrosis Model – NASH / MASH Fibrosis Models Overview Idiopathic pulmonary fibrosis MASH / NASH Systemic Sclerosis New Model Development Further in vivo models Accelerating MASH / NASH Drug Discovery with Reliable Preclinical Models Metabolic Dysfunction-associated Steatohepatitis (MASH) Developing effective therapies for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) presents major challenges—lack of reliable preclinical models,

fibrosis Model – Systemic Sclerosis Fibrosis Models Overview Idiopathic pulmonary fibrosis MASH/NASH Systemic Sclerosis New Model Development Further in vivo models Systemic Sclerosis Systemic Sclerosis (SSc or Scleroderma) stands as a complex autoimmune disease distinguished by vasculopathy, skin and internal organ fibrosis, inflammation, and overarching immune system irregularities. At MLM Medical Labs, our exploration into